FDA Approves Breakthrough Pill That Slashes Bad Cholesterol by Jaw-Dropping Percentage

Liberty Check

• First-ever daily oral PCSK9 inhibitor wins FDA approval, offering convenient alternative to injections for millions
• Clinical trials show pill cuts LDL cholesterol by up to 60% when combined with statins — roughly double the impact of statins alone
• Game-changing treatment option for patients with inherited high cholesterol or those who can’t tolerate existing medications

Millions of Americans struggling with high cholesterol just got a powerful new weapon in the fight against heart disease. The FDA has approved the first once-daily oral PCSK9 inhibitor, marking a major breakthrough in cardiovascular care.

Merck, the New Jersey-based pharmaceutical company, announced Thursday that its drug Lipfendra (enlicitide) has received federal approval. The medication blocks the action of PCSK9, a naturally occurring protein that affects how the liver removes LDL — the “bad” cholesterol — from the bloodstream.

Dr. Marc Siegel, Fox News senior medical analyst, explained the science behind this innovative treatment.

“PCSK-9 is a protein that works in the liver, preventing the recycling of LDL receptors, as a result increasing bad cholesterol in the blood. In the caveman days, this was useful when we were hunter-gatherers and didn’t always have food, but now it mainly forms plaques that lead directly to heart disease.”

The pill is approved as an add-on to diet and other LDL-lowering therapies in adults with high cholesterol, including inherited forms of the condition. In phase 3 clinical trials, Lipfendra demonstrated remarkable effectiveness, reducing LDL cholesterol by roughly 56% to 60% when combined with statin therapy.

“This is around double the impact of statins,” Siegel noted.

The medication was generally well-tolerated in clinical trials, Merck reported. The most common side effects were diarrhea and dizziness, while serious side effects and treatment discontinuations occurred at rates similar to those in the placebo group.

Statins, which work by blocking an enzyme in the liver that the body uses to make cholesterol, remain the most commonly prescribed cholesterol-lowering medications, according to the American Heart Association. For many people, statins are effective on their own.

But for some patients who have very high cholesterol levels, inherited forms of high cholesterol or adverse side effects when taking statins, another medication — such as a PCSK9 inhibitor like Lipfendra — may be necessary. Until now, PCSK9 inhibitors like Repatha and Praluent have only been available as injections, a factor experts say may have contributed to their underuse.

“Repatha, the injectable form, is very useful, with few side effects. The oral form, Lipfendra, is also well-tolerated and just as effective.”

Additional research is needed to determine whether Lipfendra also reduces the risk of heart attacks, strokes and cardiovascular deaths. Results from a large clinical trial are expected to be available in 2029, Merck stated.

Siegel added important context about cholesterol management for at-risk patients.

“Steve Nissen, longtime head of preventive cardiology at Cleveland Clinic, tells me that the lower the better when it comes to LDL cholesterol, especially in those at risk for heart disease.”

This approval represents a significant step forward in giving Americans more convenient, effective options to protect their heart health. The shift from injection to oral medication could dramatically improve patient compliance and outcomes for those battling dangerously high cholesterol levels.

Americans deserve better healthcare options that put patient convenience and effectiveness first.